25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the outcome of its recent End-of-Phase ...
Preclinical data shows strong, durable, and precise repression of HBV DNA across in vitro and in vivo models, offering a possible pathway to a functional cure ...
Plc - Director's Dealing PR Newswire LONDON, United Kingdom, November 29 29 November 20244basebio plc ("4basebio" or the "Company") Director's Dealing29 November ...